MAPT and Alzheimer disease: Jack et al.7 who also used the Lilly p-tau217 MSD assay but only in CU and Quanterix Simoa p-tau181 in CU and CI used Braak stages from 18F-flortaucipir tau PET to define AD stage and reported good group-level discrimination with plasma p-tau level.